Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 50 mg - voriconazole tablets are indicated for use in patients 12 years of age and older in the treatment of the following fungal infections: in clinical trials, the majority of isolates recovered were aspergillus fumigatus . there was a small number of cases of culture proven disease due to species of aspergillus other than a. fumigatus [see clinical studies (14.1) and clinical pharmacology (12.4) ]. [see clinical studies (14.2) and clinical pharmacology (12.4) ] [see clinical studies (14.3) and clinical pharmacology (12.4) ] [see clinical studies (14.4) and clinical pharmacology (12.4) ] specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). therapy may be instituted before the results of the cultures and other laboratory studies are known. however, once these results become available, antifungal therapy should be adjusted accordingly. - voriconazole tablets are contraindicated in patients wit

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

avera mckennan hospital - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 50 mg

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 200 mg - voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive apergillosis (ia). in clinical trials, the majority of isolates recovered were aspergillus fumigatus . there was a small number of cases of culture-proven disease due to species of aspergillus other than a. fumigatus [see clinical studies (14.1, 14.5) and microbiology (12.4)] . voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see clinical studies (14.2, 14.5) and microbiology (12.4)]. voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (ec) in adults and pediatric patients 2 years of age and older [see clinical studies (14.3, 14.5) and microbiology (12.4

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

cardinal health - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 50 mg - vfend is indicated for use in the treatment of the following fungal infections: invasive aspergillosis. in clinical trials, the majority of isolates recovered were aspergillus fumigatus . there was a small number of cases of culture-proven disease due to species of aspergillus other than a. fumigatus (see clinical studies, microbiology). candidemia in nonneutropenic patients and the following candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds (see clinical studies, microbiology). esophageal candidiasis (see clinical studies, microbiology). serious fungal infections caused by scedosporium apiospermum (asexual form of pseudallescheria boydii ) and fusarium spp. including fusarium solani, in patients intolerant of, or refractory to, other therapy (see clinical studies, microbiology). specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative o

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

cardinal health - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 200 mg

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

avpak - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 200 mg

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

talon therapeutics, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate 5 mg in 5 ml - marqibo® is indicated for the treatment of adult patients with philadelphia chromosome-negative (ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. this indication is based on overall response rate. clinical benefit such as improvement in overall survival has not been verified. marqibo is contraindicated in patients with demyelinating conditions including charcot-marie-tooth syndrome. marqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of marqibo (vincristine sulfate liposome injection). marqibo is contraindicated for intrathecal administration. pregnancy category d [see warnings and precautions (5.9) ] based on its mechanism of action and findings from animal studies, marqibo can cause fetal harm when administered to pregnant women. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 40 mg in 1 ml

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

appco pharma llc - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 50 mg - voriconazole is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections: in clinical trials, the majority of isolates recovered were aspergillus fumigatus. there was a small number of cases of culture-proven disease due to species of aspergillus other than a. fumigatus [see clinical studies (14.1), and clinical pharmacology (12.4)]. [see clinical studies (14.2), and clinical pharmacology (12.4)] [see clinical studies (14.3), and clinical pharmacology (12.4)] [see clinical studies (14.4), and clinical pharmacology (12.4)] specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). therapy may be instituted before the results of the cultures and other laboratory studies are known. however, once these results become available, antifungal therapy should be adjusted accordingly. - voriconazole is contraindicated in patients with known hypersensitiv

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 50 mg - voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive apergillosis (ia). in clinical trials, the majority of isolates recovered were aspergillus fumigatus . there was a small number of cases of culture-proven disease due to species of aspergillus other than a. fumigatus [see clinical studies (14.1, 14.5) and microbiology (12.4)].   voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see clinical studies (14.2, 14.5) and microbiology (12.4)]. voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (ec) in adults and pediatric patients 2 years of age and older [see clinical studies (14.3, 14.5) and microbiology (12.4)]. voricon